An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis.


Journal

Advances in hematology
ISSN: 1687-9104
Titre abrégé: Adv Hematol
Pays: United States
ID NLM: 101504271

Informations de publication

Date de publication:
2024
Historique:
received: 06 12 2023
revised: 24 01 2024
accepted: 05 02 2024
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 20 2 2024
Statut: epublish

Résumé

Thrombocytosis is a common reason for referral to Hematology. Differentiating between secondary causes of thrombocytosis and essential thrombocythemia (ET) is often clinically challenging. A practical diagnostic approach to identify secondary thrombocytosis could reduce overinvestigation such as next generation sequencing (NGS) panel. All adult patients with thrombocytosis (≥450 × 10 A practical approach to investigating patients with persistent thrombocytosis based on clinical characteristics such as active malignancy, chronic inflammatory disease, splenectomy, and iron deficiency may assist in accurately identifying patients more likely to have secondary causes of thrombocytosis and reduce overinvestigation, particularly costly molecular testing.

Sections du résumé

Background UNASSIGNED
Thrombocytosis is a common reason for referral to Hematology. Differentiating between secondary causes of thrombocytosis and essential thrombocythemia (ET) is often clinically challenging. A practical diagnostic approach to identify secondary thrombocytosis could reduce overinvestigation such as next generation sequencing (NGS) panel.
Methods and Results UNASSIGNED
All adult patients with thrombocytosis (≥450 × 10
Conclusion UNASSIGNED
A practical approach to investigating patients with persistent thrombocytosis based on clinical characteristics such as active malignancy, chronic inflammatory disease, splenectomy, and iron deficiency may assist in accurately identifying patients more likely to have secondary causes of thrombocytosis and reduce overinvestigation, particularly costly molecular testing.

Identifiants

pubmed: 38375212
doi: 10.1155/2024/3056216
pmc: PMC10876298
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3056216

Informations de copyright

Copyright © 2024 Ala Almanaseer et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Auteurs

Ala Almanaseer (A)

Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

Benjamin Chin-Yee (B)

Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

Jenny Ho (J)

Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

Alejandro Lazo-Langner (A)

Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

Laila Schenkel (L)

Molecular Diagnostic Division, Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada.

Pratibha Bhai (P)

Molecular Diagnostic Division, Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada.

Bekim Sadikovic (B)

Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada.

Ian H Chin-Yee (IH)

Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.
Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, Ontario, Canada.

Cyrus C Hsia (CC)

Division of Hematology, Department of Medicine, London Health Sciences Centre, London, Ontario, Canada.

Classifications MeSH